Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develop… Read more
Arcus Biosciences Inc (RCUS) - Net Assets
Latest net assets as of September 2025: $436.00 Million USD
Based on the latest financial reports, Arcus Biosciences Inc (RCUS) has net assets worth $436.00 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($974.00 Million) and total liabilities ($538.00 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $436.00 Million |
| % of Total Assets | 44.76% |
| Annual Growth Rate | 21.9% |
| 5-Year Change | -3.44% |
| 10-Year Change | N/A |
| Growth Volatility | 73.91 |
Arcus Biosciences Inc - Net Assets Trend (2016–2024)
This chart illustrates how Arcus Biosciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Arcus Biosciences Inc (2016–2024)
The table below shows the annual net assets of Arcus Biosciences Inc from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $485.00 Million | +4.98% |
| 2023-12-31 | $462.00 Million | -29.68% |
| 2022-12-31 | $657.00 Million | -21.92% |
| 2021-12-31 | $841.45 Million | +67.52% |
| 2020-12-31 | $502.30 Million | +206.58% |
| 2019-12-31 | $163.84 Million | -30.26% |
| 2018-12-31 | $234.94 Million | +52.69% |
| 2017-12-31 | $153.87 Million | +54.70% |
| 2016-12-31 | $99.46 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Arcus Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 111184800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.62 Billion | 333.40% |
| Total Equity | $485.00 Million | 100.00% |
Arcus Biosciences Inc Competitors by Market Cap
The table below lists competitors of Arcus Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BigBearai Holdings Inc
NYSE:BBAI
|
$1.72 Billion |
|
Beijing Capital Co Ltd
SHG:600008
|
$1.72 Billion |
|
Umicore SA
PINK:UMICF
|
$1.72 Billion |
|
Changshu Tianyin Electromechan
SHE:300342
|
$1.72 Billion |
|
Turkiye Garanti Bankasi AS
OTCQX:TKGBY
|
$1.71 Billion |
|
Qingdao Huicheng Environmental Co Ltd
SHE:300779
|
$1.71 Billion |
|
NuVista Energy Ltd
PINK:NUVSF
|
$1.71 Billion |
|
JUNGFRAUB. HLDG NA SF 1,5
F:J4F
|
$1.71 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Arcus Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 462,000,000 to 485,000,000, a change of 23,000,000 (5.0%).
- Net loss of 283,000,000 reduced equity.
- New share issuances of 228,000,000 increased equity.
- Other factors increased equity by 78,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-283.00 Million | -58.35% |
| Share Issuances | $228.00 Million | +47.01% |
| Other Changes | $78.00 Million | +16.08% |
| Total Change | $- | 4.98% |
Book Value vs Market Value Analysis
This analysis compares Arcus Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.20x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 5.58x to 4.20x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $4.05 | $22.59 | x |
| 2017-12-31 | $6.27 | $22.59 | x |
| 2018-12-31 | $6.79 | $22.59 | x |
| 2019-12-31 | $3.74 | $22.59 | x |
| 2020-12-31 | $9.17 | $22.59 | x |
| 2021-12-31 | $11.38 | $22.59 | x |
| 2022-12-31 | $9.13 | $22.59 | x |
| 2023-12-31 | $6.24 | $22.59 | x |
| 2024-12-31 | $5.38 | $22.59 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Arcus Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -58.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -109.69%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 2.37x
- Recent ROE (-58.35%) is below the historical average (-33.74%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -18.07% | 0.00% | 0.00x | 1.10x | $-27.92 Million |
| 2017 | -34.50% | -3756.69% | 0.01x | 1.24x | $-68.47 Million |
| 2018 | -21.11% | -593.73% | 0.03x | 1.17x | $-73.09 Million |
| 2019 | -46.34% | -506.21% | 0.07x | 1.24x | $-92.32 Million |
| 2020 | -24.49% | -157.69% | 0.10x | 1.54x | $-173.23 Million |
| 2021 | 6.30% | 13.84% | 0.24x | 1.89x | $-31.14 Million |
| 2022 | -40.64% | -238.39% | 0.08x | 2.05x | $-332.70 Million |
| 2023 | -66.45% | -262.39% | 0.11x | 2.37x | $-353.20 Million |
| 2024 | -58.35% | -109.69% | 0.22x | 2.37x | $-331.50 Million |
Industry Comparison
This section compares Arcus Biosciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Arcus Biosciences Inc (RCUS) | $436.00 Million | -18.07% | 1.23x | $1.72 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |